Zoetis Inc. $ZTS Stake Lowered by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 33.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,579 shares of the company’s stock after selling 5,913 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Zoetis were worth $1,457,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Halbert Hargrove Global Advisors LLC grew its holdings in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the last quarter. Global Wealth Strategies & Associates bought a new position in Zoetis in the 4th quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis in the 3rd quarter worth approximately $31,000. Lodestone Wealth Management LLC bought a new position in Zoetis in the 4th quarter worth approximately $30,000. Finally, Holos Integrated Wealth LLC bought a new position in Zoetis in the 4th quarter worth approximately $32,000. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $116.01 on Friday. The business has a 50 day simple moving average of $121.02 and a 200 day simple moving average of $125.73. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The firm has a market capitalization of $48.80 billion, a price-to-earnings ratio of 19.27, a price-to-earnings-growth ratio of 1.79 and a beta of 0.98. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 7.02 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. BTIG Research reissued a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $152.25.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.